A review of sixteen clinical studies with a total of 9, 011 patients with COVID-19 revealed a prevalence of DM between 2.0% and 56.6% [median (IQR)%: 13.2 (9.10 - 23.70)], highlighting the high risk that patients with DM face in the wake of the global COVID-19 pandemic (Table 1).